Fundraising FoxConstellation Pharma
AcquiredCambridge, US · 5 known investors
Find your way into Constellation Pharma
Sign up to see every warm intro you have to Constellation Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Constellation Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
Founders & leadership
JE
James E. AudiaExecutive
KD
Keith DionneExecutive
MJ
Matthias JaffeExecutive
TM
Tom ManiatisNamed on SEC filing
Board
AE
Anthony EvninBoard director
RT
DG
SP
Steven PaulBoard director
Investors · 5
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
Bain Capital Life Scienceslisted by Bain Capital Life SciencesBoston
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
The Column Grouplisted by The Column GroupSan Francisco · $30Mvia Peter Svennilson · board
How we know: The Column Group's portfolio page · board seat on SEC Form D · Not right? Tell us
Venrocklisted by VenrockPalo Alto · $500K – $10M
How we know: Venrock's portfolio page · Not right? Tell us
Third Rock VenturesreportedBoston · $100K – $5Mvia Robert Tepper · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$249.1M disclosed across 5 rounds · 2014–2019
▶$65MraisedOct 2019 · 11 investors · BiotechnologyRule 506(b)
▶$65MraisedOct 2019 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jigar RaythathaExecutive Officer, Director
- Anthony EvninDirector
- Mark A. GoldsmithDirector
- Robert TepperDirector
- James E. AudiaDirector
- Patrick TrojerExecutive Officer
- Elizabeth G. TrehuDirector
- Steven HoerterDirector
- Scott BraunsteinDirector
- Adrian SenderowiczExecutive Officer
- Karen ValentineExecutive Officer
- Emma ReeveExecutive Officer
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$99MraisedApr 2018 · 30 investors · BiotechnologyRule 506(b)
▶$99MraisedApr 2018 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jigar RaythathaExecutive Officer, Director
- Anthony EvninDirector
- Robert TepperDirector
- James E. AudiaDirector
- Emma ReeveExecutive Officer
- Mark A. GoldsmithDirector
- Peter SvennilsonDirector
- Offering amount
- $100M
- Amount sold
- $99M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.3MraisedSep 2016 · 17 investors · BiotechnologyRule 506(b)
▶$24.3MraisedSep 2016 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert TepperDirector
- Anthony EvninDirector
- James E. AudiaExecutive Officer
- Michael R. CooperExecutive Officer
- Matthias JaffeExecutive Officer
- Peter SvennilsonDirector
- Mark A. GoldsmithExecutive Officer, Director
- Tom ManiatisDirector
- Offering amount
- $24.3M
- Amount sold
- $24.3M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$55.8MraisedDec 2015 · 22 investors · BiotechnologyRule 506(b)
▶$55.8MraisedDec 2015 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom ManiatisDirector
- Michael R. CooperExecutive Officer
- Anthony EvninDirector
- James E. AudiaExecutive Officer
- Keith DionneExecutive Officer, Director
- Matthias JaffeExecutive Officer
- Mark A. GoldsmithDirector
- Robert TepperDirector
- David GoeddelDirector
- Offering amount
- $55.8M
- Amount sold
- $55.8M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedAug 2014 · 8 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert TepperDirector
- David GoeddelDirector
- Steven PaulDirector
- Michael R. CooperExecutive Officer
- Keith DionneExecutive Officer, Director
- Matthias JaffeExecutive Officer
- Mark A. GoldsmithDirector
- James E. AudiaExecutive Officer
- Tom ManiatisDirector
- Anthony EvninDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Constellation Pharma went on to found or lead other companies.
Frequently asked questions
- What does Constellation Pharma do?
- Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
- Who are Constellation Pharma's investors?
- Constellation Pharma's investors include Avoro Capital Advisors, Bain Capital Life Sciences, The Column Group, Venrock, Third Rock Ventures.
- How much funding has Constellation Pharma raised?
- Constellation Pharma has disclosed $249.1M raised across 5 rounds.
- Where is Constellation Pharma headquartered?
- Constellation Pharma is headquartered in Cambridge, US.